



⑪ Publication number : **0 579 496 A1**

⑫ **EUROPEAN PATENT APPLICATION**

⑲ Application number : 93305557.6

⑳ Date of filing : 15.07.93

⑤① Int. Cl.<sup>6</sup> : **C07D 401/04, C07D 401/06, C07D 405/04, C07D 409/04, C07D 413/14, C07D 401/14, C07D 409/14, A61K 31/505**

③① Priority : 15.07.92 US 913473  
14.06.93 US 76431

④③ Date of publication of application :  
19.01.94 Bulletin 94/03

⑥④ Designated Contracting States :  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC  
NL PT SE

⑦① Applicant : **ONO PHARMACEUTICAL CO., LTD.**  
1-5, Doshomachi 2-chome  
Chuo-ku Osaka 541 (JP)

⑦② Inventor : **Lee, Sung Jal**  
106 Church Street  
Clarks Summit, PA 18411 (US)

Inventor : **Konishi, Yoshitaka, c/o Minase Res. Institute**

**Ono Pharm. Co Ltd, 1-1 Sakurai 3-chome Shimamoto-cho, Mishima-gun, Osaka 618 (JP)**

Inventor : **Macina, Orest Taras**

**409 Applewood Acres  
Clarks Summit, PA 18411 (US)**

Inventor : **Kondo, Kigen, c/o Minase Res. Institute**

**Ono Pharm. Co. Ltd, 1-1 Sakurai 3-chome Shimamoto-cho, Mishima-gun, Osaka 618 (JP)**


Inventor : **Yu, Dingwei Tim**

**210 Frost Hollow Road  
Easton, Pa 18042 (US)**

⑦④ Representative : **Bentham, Stephen  
J.A. Kemp & Co. 14 South Square Gray's Inn  
London, WC1R 5LX (GB)**

⑤④ **4-Aminoquinazoline derivatives, and their use as medicine.**

⑤⑦ The compounds of the formula :



(I)

wherein R¹ is H or alkyl ;

Y is bond or alkylene ;

A is

(i) -CyA-(R²),

(ii) -O-R⁵ or -S(O)p-R⁵ or

(iii) -NR¹⁶R¹⁷ ;

CyA is

(1) 3-7 membered monocyclic carbocyclic ring,

(2) 4-7 membered monocyclic hetero ring containing as hetero atoms, one N atom, one N and one O atoms, two N and one O atoms, or one N and two O atoms,

(3) 4-7 membered monocyclic hetero ring containing as hetero atoms, 1 or 2 O or S atoms ;

R² is (1) H, (2) alkyl, (3) alkoxy, (4) -COOR⁵, in which R⁵ is H or alkyl, (5) -NR⁶R⁷, (6) -SO₂NR⁶R⁷, (7) halogen, (8) CF₃, (9) NO₂ or (10) CF₃O ;

Z is bond, methylene, ethylene, vinylene or ethynylene ;

R³ is H, alkyl, alkoxy, halogen or CF₃ ;

and acid addition salts thereof, salts thereof, and hydrates thereof ; have inhibitory effect on cGMP-PDE, or additionally on TXA₂ synthetase.